Inclusion Criteria:  Patient must have epithelial ovarian, fallopian tube, or primary peritoneal cancer Patients must have received ≥2 and not more than 5 prior therapies, including at least 1 line of therapy containing bevacizumab (or biosimilar). Patients must be considered platinum-resistant, defined as progression within 6 months from completion of a platinum-containing therapy Patient must be considered appropriate for treatment with weekly paclitaxel monotherapy as the next line of therapy. Patient must be willing and able to provide an FFPE archival or core tumor sample for determination of biomarker status on the Xerna™ TME Panel biomarker assay (positive or negative) prior to study treatment. Presence of at least one measurable lesion, as defined by RECIST v1.1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 Adequate organ function  Exclusion Criteria:  Non-epithelial ovarian carcinoma. Ovarian tumors with low malignant potential (i.e., borderline tumors). Primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen). Patient has received an anti-angiogenic product other than bevacizumab or biosimilar. Patient has congestive heart failure Patient has a history of myocardial infarction, cerebral vascular accident, or transient ischemic attacks within 6 months Patient has a history of cardiac ischemia or heart failure within 6 months Baseline B-type natriuretic peptide (BNP) value >100 pg/mL or N-terminal-proBNP (NT-proBNP) value of > 125 pg/mL. LVEF <50%. Peak tricuspid velocity >3.0 m/s on Doppler ECHO. Clinically significant ECG abnormality, as assessed by the investigator Blood pressure (BP) >140/90 mmHg History of bowel obstruction, including sub-occlusive disease, related to the underlying disease Hemoptysis >2.5 mL within 8 weeks prior Major surgical procedure, or significant traumatic injury within 28 days Uncontrolled seizure disorder or active neurologic disease Patients with a cardiac aneurysm.